Treating Ebola in eastern DRC

Amanda M. Rojek; Shevin Jacob; Jake Dunning

doi:10.1016/s1473-3099(20)30046-3

Treating Ebola in eastern DRC

Amanda M. Rojek
, Shevin Jacob
, Jake Dunning

Clinical Sciences

University of Melbourne
Royal Melbourne Hospital
Walimu
University of Oxford

Research output: Contribution to journal › Letter › peer-review

3 Citations (Scopus)

Abstract

Since the onset of the west Africa Ebola Virus Disease (EVD) outbreak, there has been remarkable progress in efforts to provide patients with improved supportive care and access to experimental treatments. It is reasonable to explore the potential therapeutic value of both pathogen-directed antiviral therapies and host-directed therapies (e.g., monoclonal antibody cocktails). Given unacceptably high mortality rates among EVD patients, treatments demonstrated to be safe and efficacious in clinical trials would likely be welcomed by clinicians and affected communities.

Original language	English
Pages (from-to)	284-285
Number of pages	2
Journal	The Lancet Infectious Diseases
Volume	20
Issue number	3
DOIs	https://doi.org/10.1016/s1473-3099(20)30046-3
Publication status	Published - 20 Mar 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/s1473-3099(20)30046-3

Rojek et alSubmitted manuscript, 18.9 KB

Cite this

@article{3121f34000454aff80390041d22808cd,

title = "Treating Ebola in eastern DRC",

abstract = "Since the onset of the west Africa Ebola Virus Disease (EVD) outbreak, there has been remarkable progress in efforts to provide patients with improved supportive care and access to experimental treatments. It is reasonable to explore the potential therapeutic value of both pathogen-directed antiviral therapies and host-directed therapies (e.g., monoclonal antibody cocktails). Given unacceptably high mortality rates among EVD patients, treatments demonstrated to be safe and efficacious in clinical trials would likely be welcomed by clinicians and affected communities.",

author = "Rojek, \{Amanda M.\} and Shevin Jacob and Jake Dunning",

year = "2020",

month = mar,

day = "20",

doi = "10.1016/s1473-3099(20)30046-3",

language = "English",

volume = "20",

pages = "284--285",

journal = "The Lancet Infectious Diseases",

issn = "1473-3099",

publisher = "Elsevier Ltd",

number = "3",

}

TY - JOUR

T1 - Treating Ebola in eastern DRC

AU - Rojek, Amanda M.

AU - Jacob, Shevin

AU - Dunning, Jake

PY - 2020/3/20

Y1 - 2020/3/20

N2 - Since the onset of the west Africa Ebola Virus Disease (EVD) outbreak, there has been remarkable progress in efforts to provide patients with improved supportive care and access to experimental treatments. It is reasonable to explore the potential therapeutic value of both pathogen-directed antiviral therapies and host-directed therapies (e.g., monoclonal antibody cocktails). Given unacceptably high mortality rates among EVD patients, treatments demonstrated to be safe and efficacious in clinical trials would likely be welcomed by clinicians and affected communities.

AB - Since the onset of the west Africa Ebola Virus Disease (EVD) outbreak, there has been remarkable progress in efforts to provide patients with improved supportive care and access to experimental treatments. It is reasonable to explore the potential therapeutic value of both pathogen-directed antiviral therapies and host-directed therapies (e.g., monoclonal antibody cocktails). Given unacceptably high mortality rates among EVD patients, treatments demonstrated to be safe and efficacious in clinical trials would likely be welcomed by clinicians and affected communities.

U2 - 10.1016/s1473-3099(20)30046-3

DO - 10.1016/s1473-3099(20)30046-3

M3 - Letter

SN - 1473-3099

VL - 20

SP - 284

EP - 285

JO - The Lancet Infectious Diseases

JF - The Lancet Infectious Diseases

IS - 3

ER -

Treating Ebola in eastern DRC

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this